JMP puts InterMune at market perform

InterMune, Inc. was reiterated by JMP Securities analyst Adam Cutler at market perform on news the company signed a "blockbuster" deal worth $60 million upfront with Roche for ITMN-191; InterMune's phase 1 hepatitis C protease inhibitor. The terms of the deal also include up to $470 million in potential milestone payments ($35 million within the next 12 months), with Roche funding 67% of the development costs. Shares of the Brisbane, Calif.-based biotechnology company were up $4.29, or 25.49%, at $21.12. (Nasdaq: ITMN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.